Article
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
BMJ open - 3 Jun 2021
Wang Shuhang, Huang Hui-Yao, Wu Dawei, Fang Hong, Ying Jianming, Bai Ying, Yu Yue, Fang Yuan, Jiang Ning, Sun Chao, Yu Anqi, Fan Qi, Xing Shujun, Ni Yufen, Zhang Wei, Wu Chenhua, Ji Xinqian, Wang Hui, Guo Yaqian, Tang Qiyu, Wang Yuan, Tang Yu, Li Ning
Abstract excerpt
INTRODUCTION: Limited clinical studies have been conducted on rare solid tumours, and there are few guidelines on the diagnosis and treatment, including experiences with targeted therapy and immunotherapy, of rare solid tumours in China, resulting in limited treatment options and poor outcomes. This study first proposes a definition of rare tumours and is designed to test the preliminary efficacy of targeted and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.